Baird Maintains an 'Outperform' on BioMarin Pharmaceutical (BMRN); Valuation Still Attractive, Remains a Core Holding

Baird maintains an 'Outperform' on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), raises price target to $36.00.

Baird analyst says, "Incrementally positive, raising price target after hosting an investor dinner with management this week. We are increasingly optimistic about this company’s pipeline with two un-modeled opportunities (PEG-PAL and BMN701 for Pompe disease) both poised for significant 2012 news. Coupling this with GALNS Phase III data on track for 2H12 and a steady-growth base business, we think new money would be well placed in this stock at current levels."

For more ratings news on BioMarin Pharmaceutical Inc. click here and for the rating history of BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $29.90 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy